$38.76
$96.2 B
AZN Mkt cap, 16-Aug-2018£22.5 B
AstraZeneca Revenue FY, 2017AstraZeneca Gross profit (FY, 2017)18.1 B
AstraZeneca Gross profit margin (FY, 2017), %80.8%
AstraZeneca Net income (FY, 2017)2.9 B
AstraZeneca EBITDA (FY, 2017)6.7 B
AstraZeneca EBIT (FY, 2017)3.7 B
AstraZeneca Cash, 31-Dec-20173.3 B
AstraZeneca EV95.1 B
AstraZeneca Revenue
AstraZeneca revenue was £22.46 b in FY, 2017
AstraZeneca Revenue Breakdown
AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases
AstraZeneca Income Statement
Annual
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.4 b | 5.2 b | 5.5 b | 11.4 b | 12.1 b | 11.4 b | 11.1 b | 10.5 b | 11.5 b | 14 b | 13.5 b | 14.8 b | 19.8 b | 16.9 b | 19.6 b | 19.1 b | 23 b | 22.5 b |
Revenue growth, % | 1% | (9%) | (10%) | |||||||||||||||
Cost of goods sold | 2.2 b | 2 b | 2.2 b | 3.7 b | 3.7 b | 3.1 b | 2.8 b | 2.5 b | 2.8 b | 3.1 b | 2.7 b | 3.2 b | 4.1 b | 3.5 b | 4.3 b | 3.6 b | 4.1 b | 4.3 b |
Gross profit | 3.1 b | 3.2 b | 3.4 b | 7.6 b | 8.4 b | 8.3 b | 8.3 b | 8 b | 8.7 b | 10.8 b | 10.8 b | 11.6 b | 15.7 b | 13.4 b | 15.3 b | 15.5 b | 18.9 b | 18.1 b |
Gross profit Margin, % | 58% | 62% | 61% | 67% | 70% | 73% | 75% | 76% | 76% | 78% | 80% | 78% | 79% | 80% | 78% | 81% | 82% | 81% |
Operating expense total | 2.2 b | 2.2 b | 2.4 b | 5.9 b | 5.8 b | 5.6 b | 5.8 b | 5.7 b | 6.2 b | 7 b | 6.6 b | 7.6 b | 10 b | 11 b | 13.7 b | 12.4 b | 14 b | 14.5 b |
Depreciation and amortization | 4.6 b | 3.3 b | 2.9 b | |||||||||||||||
EBITDA | 4.9 b | 4.9 b | 7 b | 3 b | 4 b | 6.7 b | ||||||||||||
EBITDA margin, % | 36% | 33% | 35% | 18% | 20% | 30% | ||||||||||||
EBIT | 942 m | 1 b | 982 m | 1.7 b | 2.7 b | 2.7 b | 2.5 b | 2.3 b | 2.6 b | 3.8 b | 4.2 b | 4.1 b | 5.7 b | 2.4 b | 1.6 b | 3.2 b | 4.9 b | 3.7 b |
EBIT margin, % | 18% | 19% | 18% | 15% | 22% | 24% | 22% | 22% | 22% | 27% | 31% | 27% | 29% | 14% | 8% | 17% | 21% | 16% |
Pre tax profit | 975 m | 1.1 b | 1 b | 1.2 b | 2.6 b | 2.8 b | 2.5 b | 2.3 b | 2.7 b | 3.9 b | 4.4 b | 4 b | 5.4 b | 2.1 b | 921.4 m | 2.4 b | 3.6 b | 2.2 b |
Income tax expense | (320 m) | (345 m) | (330 m) | (502 m) | (869 m) | (762 m) | (735 m) | (639 m) | (671 m) | (1.1 b) | (1.3 b) | (1.2 b) | (1.6 b) | (457.7 m) | (8.1 m) | (188.2 m) | (146 m) | 641 m |
Net Income | 655 m | 736 m | 715 m | 704 m | 1.7 b | 2.1 b | 1.8 b | 1.7 b | 2.1 b | 2.8 b | 3.1 b | 2.8 b | 3.8 b | 1.7 b | 913.3 m | 2.2 b | 3.4 b | 2.9 b |
- Source: Company Filings
AstraZeneca Balance Sheet
Annual
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 259 m | 303 m | 206 m | 265 m | 683 m | 489 m | 453 m | 409 m | 565 m | 2.9 b | 3.6 b | 2.9 b | 2.7 b | 6.1 b | 4.7 b | 4.8 b | 5 b | 3.3 b |
Accounts Receivable | 935 m | 969 m | 1.1 b | 1.8 b | 1.8 b | 1.7 b | 1.7 b | 1.8 b | 1.9 b | 2.2 b | 2.2 b | 2.7 b | 3.5 b | 3.6 b | 3.5 b | 3.6 b | 2.6 b | 2.8 b |
Inventories | 681 m | 728 m | 798 m | 1.3 b | 1.4 b | 1.7 b | 1.6 b | 1.7 b | 1.6 b | 1.3 b | 1.2 b | 1.1 b | 1 b | 1.3 b | 1.4 b | 1.7 b | 2.3 b | 3 b |
Current Assets | 3 b | 2.9 b | 2.7 b | 6.1 b | 7 b | 6.8 b | 7.6 b | 7.2 b | 7.7 b | 8 b | 8.7 b | 8.6 b | 10 b | 13.2 b | 12.2 b | 12.3 b | 13 b | 12.9 b |
PP&E | 1.9 b | 2.1 b | 2.4 b | 3.8 b | 3.3 b | 3.8 b | 4.1 b | 4.3 b | 4.5 b | 4.9 b | 3.8 b | 4.2 b | 4.4 b | 3.8 b | 4.4 b | 7.6 b | 10.3 b | 7.6 b |
Goodwill | 17.1 b | 24.1 b | 25.5 b | 30.4 b | ||||||||||||||
Total Assets | 5 b | 5 b | 5.5 b | 12.2 b | 12.3 b | 12.5 b | 13.5 b | 13.2 b | 13.7 b | 14.5 b | 15.3 b | 24.1 b | 29.4 b | 36.8 b | 43.3 b | 46.5 b | 62.5 b | 63.4 b |
Accounts Payable | 479 m | 529 m | 588 m | 997 m | 2 b | 1.7 b | 2 b | 1.7 b | 1.7 b | 1.8 b | 1.8 b | 1.8 b | 2.4 b | 1.6 b | 2.6 b | 2.7 b | 10.5 b | 11.6 b |
Current Liabilities | 1.9 b | 1.9 b | 2.1 b | 4.3 b | 4.6 b | 4.5 b | 5.1 b | 4.3 b | 4.2 b | 4 b | 4.8 b | 7.6 b | 8.4 b | 10.6 b | 12.8 b | 11.5 b | 15.3 b | 16.4 b |
Non-Current Liabilities | 1.1 b | 987 m | 893 m | 1.5 b | 1.3 b | 1.2 b | 1.4 b | 1.5 b | 1.8 b | 2.6 b | 2.6 b | 9 b | 11 b | 10.9 b | 16 b | 20.7 b | 32.4 b | 32 b |
Total Debt | 103 m | 76 m | 135 m | 126 m | 85 m | 75 m | 52 m | 69 m | 2.1 b | 102.3 m | 1.2 b | 144.9 m | 2.3 b | 2.2 b | ||||
Total Liabilities | 3 b | 2.8 b | 3 b | 5.9 b | 6 b | 5.7 b | 6.5 b | 5.8 b | 6 b | 6.6 b | 7.5 b | 16.6 b | 19.4 b | 21.5 b | 28.8 b | 32.2 b | 47.7 b | 48.4 b |
Additional Paid-in Capital | 237 m | 237 m | 238 m | 274 m | 296 m | 302 m | 268 m | 236 m | 220 m | 230 m | 196 m | 183 m | 227.1 m | 207.1 m | 233.7 m | 244.7 m | 316 m | 317 m |
Retained Earnings | 311 m | 365 m | 315 m | (61 m) | (245 m) | 1.2 b | 1 b | 942 m | 1.2 b | 1.8 b | 2 b | 1.5 b | 2.1 b | 1.7 b | (1.7 b) | (511.2 m) | 3.3 b | 2.7 b |
Total Equity | 2 b | 2.2 b | 2.5 b | 6.4 b | 6.4 b | 6.8 b | 7 b | 7.4 b | 7.7 b | 7.9 b | 7.8 b | 7.4 b | 10 b | 15.3 b | 14.5 b | 14.3 b | 14.9 b | 15 b |
Debt to Equity Ratio | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0.3 x | 0 x | 0.1 x | 0 x | 0.2 x | 0.2 x | ||||
Debt to Assets Ratio | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0.1 x | 0 x | 0 x | 0 x | 0 x | 0 x | ||||
Financial Leverage | 2.5 x | 2.3 x | 2.2 x | 1.9 x | 1.9 x | 1.8 x | 1.9 x | 1.8 x | 1.8 x | 1.8 x | 2 x | 3.2 x | 2.9 x | 2.4 x | 3 x | 3.2 x | 4.2 x | 4.2 x |
AstraZeneca Cash Flow
Annual
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 655 m | 736 m | 715 m | 704 m | 1.7 b | 2.1 b | 1.8 b | 1.7 b | 2.1 b | 2.8 b | 3.1 b | 2.8 b | 3.8 b | 1.7 b | 913.3 m | 2.2 b | 3.4 b | 2.9 b |
Cash From Operating Activities | 1.1 b | 1.2 b | 1.2 b | 1.9 b | 2.8 b | 2.6 b | 3.5 b | 2.4 b | 3.2 b | 3.9 b | 3.9 b | 3.8 b | 5.5 b | 4.9 b | 5.2 b | 4 b | 4.1 b | 3.6 b |
Dividends Paid | 332 m | 365 m | 399 m | 764 m | 1.9 b | 850 m | 753 m | 754 m | 833 m | 976 m | 1.1 b | 1.3 b | 1.7 b | 2.6 b | 2.7 b | |||
Cash From Financing Activities | (39 m) | (32 m) | (96 m) | (112 m) | (267 m) | (665 m) | (794 m) | (811 m) | (740 m) | (2.7 b) | (2.7 b) | 3 b | (4 b) | (2 b) | (2 b) | 3.4 b | (1.3 b) | (2.9 b) |
Net Change in Cash | 101 m | 73 m | 112 m | 172 m | 428 m | 275 m | 14 m | 2 m | 165 m | 576 m | 1.1 b | 665 m | (951.2 m) | 962.7 m | (2 b) | (28.7 m) | (1.1 b) | (1.7 b) |
Income Taxes Paid | (457.7 m) | (8.1 m) | (179.7 m) | (113.1 m) |
AstraZeneca Ratios
| GBP | Y, 2017 |
|---|---|
EV/EBITDA | 14.2 x |
EV/EBIT | 25.9 x |
EV/CFO | 26.6 x |
Revenue/Employee | 367.7 k |
Debt/Equity | 0.2 x |
Financial Leverage | 4.2 x |
Report incorrect company information
AstraZeneca Operating Metrics
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Healthcare Workers | 2.60 k | 3 k | ||
Countries | 100 | 100 | 100 | 100 |
Drugs Approved by FDA | 1 | |||
Health Facilities Activated | 250 | 403 | ||
NME in Late-stage Development | 7 | 13 | 15 | 12 |
Phase I Trials Products | 33 | 24 | 44 | 41 |
Phase II Trials Products | 27 | 11 | 33 | 36 |
Phase III Trials Products | 19 | 11 | 35 | 27 |
Projects in R&D Pipeline | 99 | 133 | 146 | 132 |
Young Health Programme Members | 1.40 m | 1.60 m |
Report incorrect company information
